We provide you with 20 years of free, institutional-grade data for UNCY stock, allowing you to gain comprehensive visibility into the fundamentals of the company. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of UNCY. Explore the full financial landscape of UNCY stock.
Total insider purchase within 3 month on this page: $0
Total insider selling within 3 month on this page: -$0
| Name | Action | Shares | Avg Price | Amount | Reported Date |
|---|
The information provided in this report about UNCY stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.
Unicycive Therapeutics, Inc.(NASDAQ:UNCY) 
Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease; and UNI 494, for treatment of acute kidney injury. The company ...
Website: https://www.unicycive.com
Founded: 2016
Full Time Employees: 9
Sector: Healthcare
Industry: Biotechnology
Share this website to your friends